- Nestle to acquire all outstanding shares of Aimmune’s common stock for $34.50/share in cash, making a total deal value as $2.6B, representing a 174% premium to Aimmune’s closing share price on Aug 28, 2020, of $12.60. The transaction is expected to close in Q4’20
- The acquisition extends Nestle’s food allergy portfolio with the addition of Palforzia, creating a broader spectrum of solutions for children living with food allergies
- Aimmune’s Palforzia is the first and only FDA-approved treatment, which helps in reducing the frequency and severity of the allergic reaction to peanuts, including anaphylaxis, in children aged 4-17yrs.
Click here to read full press release/ article | Ref: Aimmune | Image: European Coatings